Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.

Daiki TokuyasuShigeaki Suzuki Akiyuki UzawaYuriko NaganeMasayuki MasudaShingo KonnoTomoya KubotaMakoto SamukawaTakamichi SugimotoKei IshizuchiMunenori OyamaManato YasudaHiroyuki AkamineYosuke OnishiYasushi SuzukiNaoki KawaguchiNaoya MinamiTakashi KimuraMasanori P TakahashiHiroyuki MuraiKimiaki Utsugisawa

Published in: Annals of clinical and translational neurology (2024)

Eculizumab and switching to ravulizumab showed to be effective for refractory AChR+ gMG patients in clinical settings.

Keyphrases

myasthenia gravis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
patient reported